FDA and DEA Collaborate to Address Prescription Stimulant Shortage and Misuse Concerns
On August 1, 2023, The U.S. Food & Drug Administration (FDA) and the Drug Enforcement Administration (DEA) made a collective call to address the ongoing shortage of prescription stimulants in a joint letter addressed to the American public. As professionals in the legal field, this development touches especially on those of us working with pharmaceutical…